

ASX ANNOUNCEMENT**29 April 2024**

Lisa Banh
Adviser, Listings Compliance
ASX Operations
20 Bridge Street
SYDNEY NSW 2000

Dear Ms Banh

REQUEST FOR EXTENSION OF VOLUNTARY SUSPENSION

HeraMED Limited (ASX:HMD) ('HeraMED' or the 'Company') requests a further extension of its securities effective from the commencement of trading on 29 April 2024 in accordance with Listing Rule 17.2.

The Company requests that its securities remain in voluntary suspension until the earlier of 9 May 2024 or when the Company releases an announcement in relation to a proposed financing and Board changes.

As previously announced, the Company is actively engaged with third parties to secure additional funding. HeraMED intends to remain in voluntary suspension because, in its opinion, continued trading of its securities is likely to materially prejudice its ability to complete the discussions with those third parties to secure additional funding and to resolve the nature and extent of Board changes.

The Company is not aware of any reasons why the voluntary suspension should not be granted or of any other information necessary to inform the market about the voluntary suspension.

-ENDS-

This request has been authorised by the Board of HeraMED Limited.

CEO

Anoushka Gungadin

T: +61 431 131 649

E: anoushka@hera-med.com

Company Secretary

Cameron Jones

T: +61 400 086 399

E: cameron.jones@bio101.com

Investor Relations

Tim Chapman

T: +61 419 897 062

E: tchapman@claritycap.com.au